

Special Issue: Celebrating 30 years of biotechnology

Genetic approaches to interfere with malaria transmission by vector mosquitoes

Sibao Wang¹ and Marcelo Jacobs-Lorena²

¹ Key Laboratory of Insect Developmental and Evolutionary Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China

² Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA

Malaria remains one of the most devastating diseases worldwide, causing over 1 million deaths every year. The most vulnerable stages of *Plasmodium* development in the vector mosquito occur in the midgut lumen, making the midgut a prime target for intervention. Mosquito transgenesis and paratransgenesis are two novel strategies that aim at rendering the vector incapable of sustaining *Plasmodium* development. Mosquito transgenesis involves direct genetic engineering of the mosquito itself for delivery of anti-*Plasmodium* effector molecules. Conversely, paratransgenesis involves the genetic modification of mosquito symbionts for expression of anti-pathogen effector molecules. Here we consider both genetic manipulation strategies for rendering mosquitoes refractory to *Plasmodium* infection, and discuss challenges for the translation of laboratory findings to field applications.

Malaria control: present and future

Malaria is a major cause of global morbidity and mortality. Close to half of the world population is at risk; about 300–500 million contract the disease annually and more than 1 million people die of malaria every year [1]. Clearly, the available means to fight the disease are insufficient. Unlike the two other major infectious diseases – AIDS and tuberculosis – *Plasmodium*, the causative agent of malaria, is absolutely dependent on completing a complex cycle in the vector *Anopheles* mosquito for transmission to occur [2]. Thus, eliminating the mosquito or interfering with its ability to support the parasite cycle will arrest malaria transmission. Current malaria control measures targeting the mosquito vector with insecticides have helped alleviate the malaria burden in many endemic areas [3]. However, the emergence and rapid spread of insecticide-resistant mosquitoes and of drug-resistant *Plasmodium* parasites combined with the lack of an effective vaccine severely undermine current control efforts [4]. Another rarely considered but equally important limitation is that insecticides leave intact the biological niche where

mosquitoes reproduce. The mosquito populations that decline after insecticide use quickly rebound to pretreatment levels when insecticide treatment stops or becomes ineffective.

Recently, the malERA consultative group has stressed that malaria eradication cannot be achieved without introduction of novel control tools [5]. Transgenesis and paratransgenesis are two novel approaches for rendering mosquitoes refractory to *Plasmodium* infection. Here, we review recent advances on genetic approaches for interfering with the malaria parasite cycle in vector mosquitoes and consider the challenges in the translation of laboratory findings to field applications.

The malaria parasite cycle in the mosquito

Plasmodium development in the mosquito is complex and involves the completion of multiple developmental steps in the midgut (gametogenesis, fertilization, followed by zygote, ookinete and oocyst formation) and the crossing of two mosquito epithelia (midgut and salivary gland) (Figure 1a). Although thousands of gametocytes are ingested when a female mosquito feeds on an infected individual, only about 10% successfully develop into ookinetes and about five of these succeed in invading the midgut epithelium to form sessile oocysts [6]. This is followed by a dramatic amplification of parasite numbers, when each oocyst releases thousands of sporozoites into the hemocoel, after which they invade the mosquito salivary glands. The parasite is transmitted to the next individual through the bite of an infected mosquito [7]. The severe bottleneck in the mosquito gut (Figure 1b) makes this compartment a prime target for interfering with the parasite cycle in its vector [8,9].

Genetic manipulation of mosquito vectorial competence

The mosquito is essential for parasite transmission, therefore, hindering the ability of the mosquito to support parasite development will reduce or eliminate malaria transmission. One option to interfere with parasite transmission is to genetically modify the mosquito for midgut expression of effector genes, whose products inhibit parasite development. This proof of concept was

Corresponding authors: Wang, S. (sbwang@sibs.ac.cn); Jacobs-Lorena, M. (mlorena@jhsph.edu).

Keywords: malaria; transgenesis; paratransgenesis; mosquitoes; effector molecules.




Figure 1. The malaria parasite cycle in the mosquito vector. **(a)** Life cycle of *Plasmodium* in the mosquito. The approximate developmental time at which each stage occurs in *Plasmodium berghei* (maintained at 20 °C) is indicated. Transmission starts when the mosquito ingests an infected blood meal (0 h). Within minutes, gametocytes develop into gametes (the star-shaped figure illustrates exflagellation, which is the formation of male gametes) that fuse to form the zygote that differentiates into a motile ookinete. At 24 h, the ookinete invades the midgut epithelium and differentiates into an oocyst. About 2 weeks later, the oocyst ruptures, releasing thousands of sporozoites into the mosquito body cavity (hemocoel). Of all the tissues that sporozoites come in contact with, they can invade only the salivary gland. When the mosquito bites another vertebrate host, transmission is completed by release of sporozoites from the salivary glands (not shown). Reproduced, with permission, from [92]. **(b)** *Plasmodium* parasite numbers undergo a severe bottleneck during development in the mosquito gut.

tested for the first time by genetically engineering *Anopheles stephensi* for midgut expression of the salivary gland and midgut peptide 1 (SM1). This peptide binds to a putative ookinete receptor on the luminal surface of the midgut epithelium and strongly inhibits ookinete midgut invasion [10]. The genetically modified (GM) mosquitoes are substantially impaired in their ability to transmit the parasite [11]. Subsequent studies from different laboratories making use of a variety of effector molecules have reached similar conclusions [12–17]. Collectively, these studies constituted proof-of-concept that it is possible to reduce *Plasmodium* transmission via genetic modification of the vector mosquito. One crucial challenge for translating these findings to the field is to devise effective means to drive antimalarial effector genes into wild mosquito populations. It is not sufficient simply to release large numbers of transgenic mosquitoes. An effective drive mechanism must be devised to give mosquitoes carrying effector genes a competitive advantage. Of several potential approaches that have been proposed, including the use of transposable elements or *Wolbachia*, two – MEDEA (maternal-effect dominant embryonic arrest) and HEG (homing endonuclease gene) – are particularly promising. The MEDEA drive system has shown promise in experiments using the *Drosophila* model system [18]. The approach is based on linking the effector gene to a toxin that in the ovary inactivates a maternal gene essential for embryonic development, and a zygotic antidote that rescues the defect by early zygotic expression of the same maternal gene. The technologies for transferring this approach to mosquitoes (e.g., identification of mosquito

maternal effect genes and of mosquito embryonic promoters for the rescue constructs) have not yet been developed. The *Drosophila* experiments have indicated that a high initial introduction rate (~25%) is required, which may constitute a limiting factor for field applications. More recently, another promising approach has been explored that makes use of the HEG drive system [19,20]. This study has shown that in cage experiments, the homing endonuclease gene *I-SceI* can rapidly spread among the transgenic *Anopheles gambiae* progeny. An additional consideration for any gene drive approach is that there are around 430 anopheline species; about 30–40 of which are natural vectors for human malaria [21], and few of them have been shown to be amenable to genetic manipulation [22]. Moreover, anopheline vectors frequently exist as reproductively isolated populations (cryptic species) [23], thus preventing gene flow from one population to another. In addition, fitness load imposed by refractory genes, insertional mutagenesis and positional effects will have to be considered [15,24,25]. Once these issues are resolved, transgenesis could provide a powerful tool to combat malaria.

Antimalarial effector genes

The identification of efficient anti-*Plasmodium* effector genes is an essential prerequisite for the generation of a refractory mosquito. Ideally, the effector molecules should interfere with parasite transmission without imposing a fitness cost to the mosquito. Based on their mode of action, the existing anti-*Plasmodium* effector molecules can be grouped into four classes (Table 2).

- (i) **Parasite killing.** This class includes peptides from the innate immune system of the insect, such as defensins [26], gambicin [27], and cecropins [28], and peptides from other sources that lyse parasites but do not affect the host insect, such as scorpine, a scorpion antimalarial lytic peptide that has hybrid properties of the lytic peptides cecropin and defensin [29,30], Hemolytic C-Type Lectin CEL-III [13], angiotensin II [31], magainins [32], synthetic antiparasitic lytic peptides Shiva-1 and Shiva-3 [33], and gomesin [34].
- (ii) **Interaction with parasites.** EPIP, a *Plasmodium* enolase–plasminogen interaction peptide, is a peptide that inhibits mosquito midgut invasion by preventing plasminogen binding to the ookinete surface [35]. Other agents are single-chain monoclonal antibodies (scFvs) that bind to ookinete or sporozoite surface or secreted proteins. For instance, scFv 4B7 binds to *P. falciparum* ookinete surface protein Pfs25, 2A10 targets the *P. falciparum* circumsporozoite protein (CSP) [16,36], anti-Pbs21 single chain antibody targets the *Plasmodium berghei* major ookinete surface protein Pbs21 [37], and scFv 1C3 binds a *P. falciparum* secreted enzyme chitinase 1 [16].
- (iii) **Interaction with mosquito midgut or salivary gland epithelia.** Examples of this class are SM1 – a 12-amino acid peptide, which binds to putative receptors on the luminal surface of the mosquito midgut and basal surface of the salivary gland epithelia, blocking ookinete and sporozoite invasion [10]; mPLA2 is a mutant phospholipase A2 that inhibits ookinete invasion, possibly by modifying the properties of the midgut epithelial membrane [12,30,38]; and a chitinase propeptide that inhibits this enzyme and in this way hinders ookinete traversal of the mosquito peritrophic matrix (PM) [39]. The PM is a chitin-based extracellular structure that surrounds the entire blood meal and must be crossed by the ookinete for reaching the mosquito midgut [40].
- (iv) **Manipulation of mosquito immune system.** Several laboratories have shown that alteration of mosquito immune-related genes can lead to decreased mosquito vectorial competence. Blood-meal-induced expression of Akt, a key signaling component in the insulin signaling pathway renders the mosquito refractory to *Plasmodium* infection [15]. Overexpression of IMD pathway-mediated transcription factor Rel2 renders the mosquito resistant to *Plasmodium* infection [14]. Manipulation of mosquito to the immune pathway using RNA interference or ‘smart sprays’ enhances mosquito antimicrobial response [41,42].

We note that the identification of efficient effector molecules is as valuable to transgenesis as to paratransgenesis. A potential issue regarding antimalarial effector molecules is that, in the long run, parasites may develop resistance to their action in similar ways that they develop resistance to drugs that kill them in the human blood. For this reason, it will be important to combine multiple anti-*Plasmodium*

effector proteins with different modes of action. In addition, the use of multiple effector genes will also maximize the effectiveness of interference with parasite development (additive or synergistic effects).

Genetic manipulation of mosquito pathogenic fungi and viruses

Insect fungal pathogens, *Metarhizium robertsii* and *Beauveria bassiana* are natural killers of insects including mosquitoes [43]. Several studies have highlighted the promising use of insect fungal pathogens for controlling adult malaria mosquitoes and reducing malaria transmission rates [44–49]. Recently, *M. robertsii* was genetically engineered to deliver anti-*Plasmodium* peptides or proteins into the mosquito hemocoel for killing sporozoites or preventing sporozoite invasion of mosquito salivary glands. The transgenic fungi significantly reduced sporozoite density in salivary glands [50], indicating that genetic modification of pathogenic fungi provides an enhanced tool to reduce malaria transmission.

Linear single-stranded DNA densoviruses have also been found to infect several important vector mosquitoes (*Aedes aegypti* [51], *A. gambiae* [52], and *Culex pipiens* [53]), and to be vertically transmitted [52,54]. The *A. gambiae* densovirus (AgDNV) has been found to infect efficiently *A. gambiae* larvae and to spread to the adult midgut, fat body, and ovaries [52]. This virus has also been found to be vertically transmitted to subsequent mosquito generations [52]. These properties suggest that densoviruses could be used to produce effector molecules in host mosquitoes [54]. However, the limited length of foreign DNA that these viruses can carry may become a limiting factor.

Mosquito symbionts and other associated organisms

Microbial associations with insects are ubiquitous and play an important role in shaping many aspects of insect digestive physiology, ecological adaptation, and evolution. The gut microbiota is thought to be beneficial to the mosquito by providing nutritional supplements, tolerance to environmental perturbations, and manipulation of host immune homeostasis [55]. Recently, the association between symbionts and their hosts has attracted increased attention from the perspective of their engineering to combat pathogens [56–60]. Many bacterial species have been identified from the midgut of field-collected anophelines; mostly Gram-negative proteobacteria and enterobacteria [61,62]. The bacterial population structure in laboratory-reared adult mosquitoes has been found to be similar to that of wild mosquitoes, suggesting that anopheline mosquitoes harbor their microbiota in a selective way [62]. A non-pathogenic bacterium, *Pantoea agglomerans*, has been reported to be a dominant symbiotic bacterium in different mosquito species in Kenya and Mali [61], and also found in laboratory-reared *A. stephensi*, *A. gambiae* and *An. albimanus* mosquitoes [60,63]. This bacterium is normally found on plant surfaces and blossoms [64–66], suggesting that flower nectar is a possible source of the mosquito microbiota in the field. Also, this property could potentially facilitate reintroduction of GM *P. agglomerans* into field mosquito populations.

The bacterial population in the mosquito gut increases by hundreds to thousands of times within 24 h after a blood meal [30,63]. The rapid proliferation of gut microbiota may stimulate mosquito immune responses that limit infection by malaria parasites [67,68]. Reduction of the gut microbiota with antibiotics renders the mosquito more susceptible to *Plasmodium* infection. Conversely, co-infection of bacteria with *Plasmodium* gametocytes reduces the oocyst load in the mosquito midgut [67]. Recently, an *Enterobacter* bacterium strain Esp_Z, isolated from wild *Anopheles arabiensis* mosquitoes in Zambia was found to inhibit significantly *P. falciparum* infection after co-feeding *A. gambiae* with bacteria and infectious blood. Reactive oxygen species (ROS) produced by this bacterium seem to mediate parasite killing in the midgut lumen prior to mosquito midgut invasion [69]. A recent study has revealed a positive correlation between the abundance of commensal *Enterobacteriaceae* and *Plasmodium* infection in *A. gambiae* mosquito midgut, and has suggested that *Enterobacteriaceae* might play a positive protective role in the natural infection of *P. falciparum* [70].

The acetic acid bacterium *Asaia* sp. has been identified as stable symbiont in laboratory *A. stephensi* colonies and in wild *A. gambiae* populations. *Asaia* sp. have also been observed in several mosquito organs, including salivary glands and ovaries [58]. Importantly, *Asaia* sp. appear to be vertically transmitted from female to larval progeny, venereally from male to female during mating, and transstadially from larvae to adults [58,71,72]. These features favor dissemination and should be helpful when considering potential introduction of GM bacteria into mosquito populations in the field.

The intracellular endosymbiotic bacterium *Wolbachia* can infect a large number of insects and other arthropod species, and may play key roles in modulating pathogen infection and transmission in several insect species [73,74]. Recent studies have shown that *Wolbachia* infection reduces pathogen levels in multiple mosquito species [75–77]. Somatic *Wolbachia* infections of *Anopheles* can also significantly inhibit *Plasmodium* oocyst formation through activation of the mosquito immune system [78]. However, *Wolbachia*-infected anopheline mosquitoes have not been found in nature and stable mosquito infections have not yet been reported [79].

Several yeasts such as *Candida*, *Pichia*, and *Wickerhamomyces anomalus* have been found in the guts of *Anopheles* mosquitoes [80–82]. Moreover, *W. anomalus* has also been identified in the reproductive organs of malaria vectors *A. gambiae* and *A. stephensi* [81,82], raising the possibility of use of symbiotic yeasts for delivery of antimalarial effector proteins to anopheline vectors.

Paratransgenesis

Paratransgenesis refers to the genetic engineering of a microorganism associated with its insect host, as opposed to genetic modification of the insect itself. At the heart of the paratransgenesis strategy for malaria control is the fact that the mosquito microbiota and *Plasmodium* share the same compartment – the midgut – where the most vulnerable stage of the parasite development occurs (Figure 1b). These considerations suggest an alternate

approach to interfere with malaria transmission by genetically engineering midgut symbiotic microorganisms to deliver anti-*Plasmodium* effector molecules [83]. Paratransgenesis has a number of attractive features [84]: (i) as for most higher organisms, the mosquito carries a significant microbiota in its midgut; (ii) a severe bottleneck of *Plasmodium* development occurs in the mosquito midgut lumen, making this compartment a prime target for intervention [8,9]; (iii) the developing parasite and microbiota share the same midgut compartment, directly exposing parasites to molecules produced by engineered symbiotic bacteria; and (iv) the midgut bacterial population increases dramatically, by 100- to 1000-fold, after ingestion of a blood meal [7], correspondingly increasing the output of effector molecules produced by recombinant bacteria (Figure 2a,b). The basic requirements for a paratransgenesis approach are listed in Table 1.

Paratransgenesis has already been proposed as a feasible means to control other insect-borne diseases. The parasitic protozoan *Trypanosoma cruzi*, the causative agent of Chagas disease, is transmitted by the triatomid bug *Rhodnius prolixus* [56]. The *Rhodnius* obligate Gram-positive bacterium *Rhodococcus rhodnii* has been genetically engineered to produce the antimicrobial peptide cecropin A, and fed to naïve *R. prolixus* nymphs. Durvasula and collaborators [56] have shown that expression of the anti-parasite peptide by the GM symbionts significantly reduces the ability of *T. cruzi* to survive in the bug.

Fighting malaria with paratransgenesis

Early reports on the use of paratransgenesis to fight malaria were based on the recombinant laboratory bacterium *Escherichia coli* expressing a single-chain immunotoxin [85]. In another study, a dimer of the SM1 peptide or a modified phospholipase A2 [60] was used, resulting in a significant decrease of *P. berghei* oocyst numbers in *A. stephensi*. However, inhibition of parasite development was modest for two main reasons: (i) the *E. coli* used for these studies were attenuated laboratory strains that survived poorly in the mosquito midgut; and (ii) the recombinant anti-*Plasmodium* effector proteins either formed insoluble inclusion bodies [37] or were attached to the bacterial surface [60]. In either case, the effector molecules could not diffuse to their intended parasite or mosquito midgut targets.

Some of these shortcomings have been addressed in recent studies with *P. agglomerans* a bacterium commonly found in field vector mosquitoes in Africa [61], as well as in laboratory-reared *A. stephensi*, *A. gambiae*, and *A. albimanus* [60,63]. *P. agglomerans* easily grows in culture and can be engineered to secrete anti-*Plasmodium* proteins using the HlyA system [30,86]. The engineered bacteria have been tested for their ability to thwart *Plasmodium* development in the mosquito as follows. Recombinant bacteria were fed to mosquitoes via cotton balls soaked with a bacteria suspension in sugar solution. One day later, these mosquitoes were fed on a *Plasmodium*-infected blood meal. Control mosquitoes were fed bacteria transformed with the HlyA parental plasmid not fused to an effector protein. One or two weeks after the infectious blood meal, success of parasite development was measured




Figure 2. Engineered *Pantoea agglomerans* efficiently inhibits *Plasmodium falciparum* development in mosquitoes. **(a)** Visualization of GFP-tagged *P. agglomerans* in the mosquito midgut 24 h after a blood meal. GFP-expressing *P. agglomerans* was administered to 2-day-old *Anopheles gambiae* via a sugar meal. The upper mosquito fed on wild type bacteria, and the lower mosquito fed on GFP-tagged bacteria. **(b)** *P. agglomerans* rapidly proliferated in the midgut after a blood meal. The number of fluorescent bacteria colony-forming units (CFU) was determined at each of the indicated times by plating serially diluted midgut homogenates on LB/kanamycin agar plates. **(c)** Inhibition of *P. falciparum* development in *A. gambiae* by recombinant *P. agglomerans* engineered to secrete scorpine, a potent antiplasmodial peptide. Wild type *P. agglomerans* was fed to one group of *A. gambiae* mosquitoes via a sugar meal and *P. agglomerans* engineered to secrete scorpine was fed to the other group of mosquitoes. After 32 h both groups of mosquitoes were fed on the same *P. falciparum*-infected blood meal. Midguts were dissected 8 days post-infection and oocyst number per midgut was determined after staining with 0.1% (wt/vol) mercurochrome. Left panel: a midgut from a mosquito carrying scorpine-secreting *P. agglomerans*; right panel: a midgut from a control mosquito carrying an equal number of wild type *P. agglomerans*. Note the strong reduction in oocyst numbers in the midgut from the mosquito fed scorpine-secreting bacteria.

by counting the number of oocysts per gut (only ookinetes that successfully cross the mosquito midgut epithelium can form oocysts). These experiments have shown that recombinant bacteria secreting antimalarial effector proteins strongly inhibit *Plasmodium* development in mosquitoes, as compared with mosquitoes fed control bacteria (Figure 2c). Inhibition varied from 85% for mPLA2 to 98% for scorpine and (EPIP)₄ without any detectable fitness cost to the transgenic bacteria [87] or to the host mosquitoes [30]. Considering that a mosquito that produces one oocyst is as infective to a human host as a mosquito producing a large number of oocysts, a more

important measure of transmission-blocking potential is to compare the number of infected mosquitoes carrying one or more oocysts (infected mosquitoes) with the number of noninfected mosquitoes. In the experiments described above, the percentage of infected mosquitoes dropped from 90% in controls to 14–18% in mosquitoes carrying scorpine- or (EPIP)₄-expressing bacteria [30]. This strong reduction in the proportion of infected mosquitoes should translate into important reduction of transmission in the field. Moreover, the use of multiple effector molecules, each acting by a different mechanism, should greatly reduce the probability of selecting resistant parasites. The inhibition of parasite development is equivalent when using an African mosquito (*A. gambiae*) and an Asian mosquito (*A. stephensi*). Also, inhibition of *P. berghei* (a rodent parasite) and *P. falciparum* (a human parasite) is equivalent, suggesting that this approach may also work for other human parasites, such as *Plasmodium vivax*. Thus, the paratransgenesis strategy may well turn out to be universal, being effective for multiple mosquito and parasite species. These promising laboratory results will next need to be translated to field applications. A major outstanding issue is how to introduce efficiently the engineered bacteria into wild mosquito populations. Although some approaches have

Table 1. Basic requirements for paratransgenesis

i	Stable symbiotic relationship between microorganism and vector
ii	Symbiotic microorganism can be cultured <i>in vitro</i> and genetically manipulated
iii	Effector gene product should not impair symbiont and vector fitness
iv	Effector gene product should be secreted to assure interaction with the target pathogen
v	An efficient means of introducing the engineered symbiont into field must be devised

Table 2. Anti-*Plasmodium* effector molecules

Effector	Properties	Target parasite	Parasite stages	Function or mechanism	Refs
Parasite killing					
Scorpine	Scorpion <i>Pandinus imperator</i> venom peptide	<i>P. falciparum</i> <i>P. berghei</i>	Gametocyte to Ookinete	Cecropin and defensin-like lytic peptide.	[29]
Shiva1	Cecropin-like synthetic peptide	<i>P. berghei</i> <i>P. falciparum</i>	Gametocyte to Ookinete	Lyses parasites	[93]
Shiva-3	Cecropin-like synthetic peptide	<i>P. falciparum</i> <i>P. berghei</i>	Gametocyte to ookinete	Lyses parasites	[33]
Cec A	<i>A. gambiae</i> cecropin A	<i>P. berghei</i>	Ookinete	Lyses parasites	[28]
Cec B	<i>A. gambiae</i> cecropin B	<i>P. falciparum</i>	Oocyst	Lyses parasites	[32]
DEF1 A	<i>A. gambiae</i> defensin A	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Lyses parasites	[26]
Gambicin	<i>A. gambiae</i> antimicrobial peptide	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Lyses parasites	[27]
Angiotensin II		<i>P. gallinaceum</i>	Sporozoite	Lyses parasites	[31]
Magainins	Peptides from the African clawed frog <i>Xenopus laevis</i> skin	<i>P. falciparum</i> <i>Plasmodium knowlesi</i> <i>Plasmodium cynomolgi</i>	All mosquito stages	Lyses parasites	[32]
Gomesin	A antimicrobial peptide from Spider	<i>P. falciparum</i> <i>P. berghei</i>	All mosquito stages	Lyses parasites	[34]
CEL-III	Hemolytic C-Type Lectin	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete, oocyst	Lyses parasites	[13]
TP10	Wasp venom peptide	<i>P. falciparum</i>	Gametocyte to ookinete	Lyses the parasites	[94]
AdDLP	<i>Anaeromyxobacter dehalogenans</i> defensin-like peptide	<i>P. berghei</i>	Ookinete	Lyses the parasites	[95]
Meucin-25	Scorpion <i>Mesobuthus eupeus</i> venom gland	<i>P. berghei</i> <i>P. falciparum</i>	Gametocyte	Anti-microbial linear cationic peptide	[96]
Drosomycin	An inducible antifungal peptide initially isolated from the <i>Drosophila melanogaster</i> hemolymph	<i>P. berghei</i>	Ookinete	Lyses the parasites	[97]
Interaction with parasites					
EPIP	Enolase–plasminogen interaction peptide	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Inhibits mosquito midgut invasion by preventing plasminogen binding to the ookinete surface	[35]
Pro:EPIP	A fusion peptide composed of a chitinase propeptide (Pro) and EPIP	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Blocks ookinete traversal of the mosquito peritrophic matrix and prevents plasminogen binding to the ookinete surface	[30]
Pbs21scFv-Shiva1	Single-chain immunotoxin	<i>P. falciparum</i> <i>P. berghei</i>	Gametocyte to oocyst	An scFv targeting the major ookinete surface protein pbs21 and linked to the lytic peptide Shiva1	[37]
scFv 4B7	A single-chain antibody	<i>P. falciparum</i>	Ookinete	Binds to <i>P. falciparum</i> ookinete surface protein Pfs25	[16,36]
scFv 2A10	Single-chain antibody	<i>P. falciparum</i>	Ookinete	Targets the <i>P. falciparum</i> CSP	[16,36]
PfNPNA-1	Single-chain antibody	<i>P. falciparum</i>	Sporozoite	Recognizes the repeat region (Asn-Pro-Asn-Ala) of the <i>P. falciparum</i> surface CSP	[50]
scFv 1C3	Single-chain antibody	<i>P. falciparum</i>	Ookinete	Binds a <i>P. falciparum</i> secreted enzyme chitinase 1	[16]
Interaction with mosquito midgut or salivary gland epithelia					
SM1	Salivary gland and midgut peptide 1	<i>P. berghei</i> <i>P. falciparum</i>	Ookinete, sporozoite	Blocks ookinete invasion of the midgut epithelium or sporozoite invasion of the salivary gland epithelium	[10]
mPLA2	Bee venom phospholipase	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Inhibits ookinete midgut invasion, probably by modifying the properties of the midgut epithelial membrane	[12]

Table 2 (Continued)

Effector	Properties	Target parasite	Parasite stages	Function or mechanism	Refs
Pro	A chitinase propeptide	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Inhibits the enzyme and blocks ookinete traversal of the mosquito peritrophic matrix	[39]
Pch2scfv	Single-chain antibody	<i>P. falciparum</i>	Ookinete	Inhibits the <i>P. falciparum</i> chitinase and blocks ookinete traversal of the mosquito peritrophic matrix	[98]
Manipulation of mosquito immune system					
Akt	A protein kinase	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete	Akt boosts mosquito innate immunity via insulin signaling	[15]
Rel2	<i>Anopheles</i> IMD pathway transcription factor	<i>P. falciparum</i> <i>P. berghei</i>	Ookinete, sporozoite	Rel2 overexpression enhances mosquito IMD pathway	[14]

Box 1. Genetic manipulation of mosquito vectorial competence via transgenesis and paratransgenesis

Mosquito transgenesis has the advantage of having no off-target effects because transgene expression is restricted to the engineered mosquito. The anti-*Plasmodium* effector genes can be engineered to express in specific tissues (midgut, fat body, and salivary glands), only in females, and in a blood-induced manner. Although it has been shown that a mostly refractory mosquito can be produced in the laboratory, challenges remain for translating these findings to field applications. A method to drive effector genes into mosquitoes in the field still needs to be devised. The MEDEA [18] and homing nuclease (HEG) [19] approaches are among the most promising ones. Additional issues that need to be considered are the multiplicity of anopheline vector species (each needs to be separately engineered), the reproductive barriers within a given species (cryptic species), mass production and sex selection of transgenic mosquitoes (females cannot be mass-released in the field), the large size of the constructs expressing multiple effector genes, and the possible loss of transgene expression over time [99].

Paratransgenesis refers to an alternative approach for delivery of effector molecules via the genetic modification of mosquito symbionts. Advantages of paratransgenesis are the simplicity of genetic modification of bacteria, the ease of growing the genetically modified bacteria in large scale, the fact that it bypasses genetic barriers of reproductively isolated mosquito populations, and effectiveness does not appear to be influenced by mosquito species. However, many challenges lie ahead. A major challenge is to devise effective means to introduce engineered bacteria into field mosquito populations. This may be accomplished by placing around villages, bating stations (cotton balls soaked with sugar and bacteria placed in clay jar refuges) [100] using engineered symbiotic bacteria that are vertically and horizontally transmitted among mosquito populations [58]. However, no experimental evidence for the effectiveness of such an approach is presently available. Moreover, for future use in the field, the effector genes need to be integrated into the bacterial genome to avoid gene loss and also to minimize the risk of horizontal transgene transfer.

For both the transgenic and the paratransgenic approaches, a major challenge for ultimate implementation will be to obtain the required approval from regulatory agencies and from the local population.

been proposed (Box 1), none have as yet been experimentally verified.

Concluding remarks

Current insecticide-based vector control strategies such as insecticide-impregnated bed nets, as well as other population-suppression strategies [e.g., sterile-insect

technique (SIT) [88,89] or RIDL (release of insects carrying a dominant lethal) [90] have the disadvantage that they create an empty ecological niche. This is because the use of these approaches leaves the environment where mosquitoes thrive unchanged, and consequently, mosquito populations revert to original density as soon as treatments end or when mosquitoes become resistant to the insecticide. In other words, any population-suppression strategy needs to be implemented forever.

Transgenesis and paratransgenesis are two novel promising means for interfering with *Plasmodium* development or infection of the vector mosquito through delivery of anti-*Plasmodium* effector molecules within the mosquito. Both are population-replacement strategies that, once implemented, should require much less follow-up effort than population-suppression strategies. The main properties of transgenesis and paratransgenesis are shown in Box 1. Although many technical aspects have been successfully addressed, several major issues need to be resolved before transgenesis and paratransgenesis can be implemented in the field. One key issue for both approaches is to devise means to drive effectively transgenes or the engineered bacteria into mosquito populations in the field. Other major topics that need to be addressed are the resolution of regulatory, ethical, and public acceptance issues relating to the release of GM organisms in nature. Although the GM subject is controversial, its resolution will ultimately rely on weighing risks against benefits. As these issues are considered, the benefit of saving lives should provide a strong argument in its favor.

Transgenesis or paratransgenesis is not a cure-all solution for malaria control. Rather, both are envisioned as a complement to existing and future control measures. In this regard, transgenesis and paratransgenesis are compatible with each other (possibly additive) and with insecticides and population suppression approaches. Moreover, the diversity of effector proteins [91] make both approaches not unique to malaria but might also be extended to the control of other major mosquito-borne diseases, such as dengue and yellow fever.

Acknowledgments

Work in our laboratory was supported by a grant from the National Institute of Allergy and Infectious Diseases.

References

- 1 Murray, C.J. *et al.* (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. *Lancet* 379, 413–431
- 2 Ghosh, A. *et al.* (2000) The journey of the malaria parasite in the mosquito: hopes for the new century. *Parasitol. Today* 16, 196–201
- 3 Greenwood, B.M. *et al.* (2008) Malaria: progress, perils, and prospects for eradication. *J. Clin. Invest.* 118, 1266–1276
- 4 Trape, J.F. *et al.* (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. *Lancet Infect. Dis.* 11, 925–932
- 5 The malERA Consultative Group on Basic Science Enabling Technologies (2011) A research agenda for malaria eradication: basic science and enabling technologies. *PLoS Med.* 8, e1000399
- 6 Taylor, L.H. (1999) Infection rates in, and the number of *Plasmodium falciparum* genotypes carried by *Anopheles* mosquitoes in Tanzania. *Ann. Trop. Med. Parasitol.* 93, 659–662
- 7 Whitten, M.M.A. *et al.* (2006) Mosquito midguts and malaria: cell biology, compartmentalization and immunology. *Parasite Immunol.* 28, 121–130
- 8 Abraham, E.G. and Jacobs-Lorena, M. (2004) Mosquito midgut barriers to malaria parasite development. *Insect Biochem. Mol. Biol.* 34, 667–671
- 9 Drexler, A.L. *et al.* (2008) *Plasmodium* development in the mosquito: biology bottlenecks and opportunities for mathematical modeling. *Trends Parasitol.* 24, 333–336
- 10 Ghosh, A.K. *et al.* (2001) Targeting *Plasmodium* ligands on mosquito salivary glands and midgut with a phage display peptide library. *Proc. Natl. Acad. Sci. U.S.A.* 98, 13278–13281
- 11 Ito, J. *et al.* (2002) Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. *Nature* 417, 452–455
- 12 Moreira, L.A. *et al.* (2002) Bee venom phospholipase inhibits malaria parasite development in transgenic mosquitoes. *J. Biol. Chem.* 277, 40839–40843
- 13 Yoshida, S. *et al.* (2007) Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic mosquitoes impairs malaria parasite development. *PLoS Pathog.* 3, e192
- 14 Dong, Y. *et al.* (2011) Engineered anopheles immunity to *Plasmodium* infection. *PLoS Pathog.* 7, e1002458
- 15 Corby-Harris, V. *et al.* (2010) Activation of Akt signaling reduces the prevalence and intensity of malaria parasite infection and lifespan in *Anopheles stephensi* mosquitoes. *PLoS Pathog.* 6, e1001003
- 16 Isaacs, A.T. *et al.* (2011) Engineered resistance to *Plasmodium falciparum* development in transgenic *Anopheles stephensi*. *PLoS Pathog.* 7, e1002017
- 17 Abraham, E.G. *et al.* (2005) Driving midgut-specific expression and secretion of a foreign protein in transgenic mosquitoes with AgAper1 regulatory elements. *Insect Mol. Biol.* 14, 271–279
- 18 Chen, C.H. *et al.* (2007) A synthetic maternal-effect selfish genetic element drives population replacement in *Drosophila*. *Science* 316, 597–600
- 19 Windbichler, N. *et al.* (2011) A synthetic homing endonuclease-based gene drive system in the human malaria mosquito. *Nature* 473, 212–215
- 20 Deredec, A. *et al.* (2011) Requirements for effective malaria control with homing endonuclease genes. *Proc. Natl. Acad. Sci. U.S.A.* 108, E874–E880
- 21 National Center for Infectious Disease (2004) *Mosquitoes. Division of Parasitic Disease*, p. 6
- 22 Coutinho-Abreu, I.V. *et al.* (2010) Transgenesis and paratransgenesis to control insect-borne diseases: current status and future challenges. *Parasitol. Int.* 59, 1–8
- 23 Powell, J.R. *et al.* (1999) Population structure, speciation, and introgression in the *Anopheles gambiae* complex. *Parassitologia* 41, 101–113
- 24 Catteruccia, F. *et al.* (2003) Impact of genetic manipulation on the fitness of *Anopheles stephensi* mosquitoes. *Science* 299, 1225–1227
- 25 Li, C. *et al.* (2008) Fitness of transgenic *Anopheles stephensi* mosquitoes expressing the SM1 peptide under the control of a vitellogenin promoter. *J. Hered.* 99, 275–282
- 26 Kokoza, V. *et al.* (2010) Blocking of *Plasmodium* transmission by cooperative action of Cecropin A and Defensin A in transgenic *Aedes aegypti* mosquitoes. *Proc. Natl. Acad. Sci. U.S.A.* 107, 8111–8116
- 27 Vizioli, J. *et al.* (2001) Gambicin: a novel immune responsive antimicrobial peptide from the malaria vector *Anopheles gambiae*. *Proc. Natl. Acad. Sci. U.S.A.* 98, 12630–12635
- 28 Kim, W. *et al.* (2004) Ectopic expression of a cecropin transgene in the human malaria vector mosquito *Anopheles gambiae* (Diptera: Culicidae): effects on susceptibility to *Plasmodium*. *J. Med. Entomol.* 41, 447–455
- 29 Conde, R. *et al.* (2000) Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom. *FEBS Lett.* 471, 165–168
- 30 Wang, S. *et al.* (2012) Fighting malaria with engineered symbiotic bacteria from vector mosquitoes. *Proc. Natl. Acad. Sci. U.S.A.* 109, 12734–12739
- 31 Maciel, C. *et al.* (2008) Anti-plasmodium activity of angiotensin II and related synthetic peptides. *PLoS ONE* 3, e3296
- 32 Gwadz, R.W. *et al.* (1989) Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. *Infect. Immun.* 57, 2628–2633
- 33 Possani, L.D. *et al.* (1998) From noxiustoxin to Shiva-3, a peptide toxic to the sporogonic development of *Plasmodium berghei*. *Toxicon* 36, 1683–1692
- 34 Moreira, C.K. *et al.* (2007) Effect of the antimicrobial peptide gomesin against different life stages of *Plasmodium* spp. *Exp. Parasitol.* 116, 346–353
- 35 Ghosh, A.K. *et al.* (2011) *Plasmodium* ookinetes coopt mammalian plasminogen to invade the mosquito midgut. *Proc. Natl. Acad. Sci. U.S.A.* 108, 17153–17158
- 36 de Lara Capurro, M. *et al.* (2000) Virus-expressed, recombinant single-chain antibody blocks sporozoite infection of salivary glands in *Plasmodium gallinaceum*-infected *Aedes aegypti*. *Am. J. Trop. Med. Hyg.* 62, 427–433
- 37 Yoshida, S. *et al.* (2001) Bacteria expressing single-chain immunotoxin inhibit malaria parasite development in mosquitoes. *Mol. Biochem. Parasitol.* 113, 89–96
- 38 Zieler, H. *et al.* (2001) A snake venom phospholipase A(2) blocks malaria parasite development in the mosquito midgut by inhibiting ookinete association with the midgut surface. *J. Exp. Biol.* 204, 4157–4167
- 39 Bhatnagar, R.K. *et al.* (2003) Synthetic propeptide inhibits mosquito midgut chitinase and blocks sporogonic development of malaria parasite. *Biochem. Biophys. Res. Commun.* 304, 783–787
- 40 Shao, L. *et al.* (2001) The peritrophic matrix of hematophagous insects. *Arch. Insect Biochem. Physiol.* 47, 119–125
- 41 Christophides, G.K. *et al.* (2004) Comparative and functional genomics of the innate immune system in the malaria vector *Anopheles gambiae*. *Immunol. Rev.* 198, 127–148
- 42 Brown, A.E. *et al.* (2003) Stable and heritable gene silencing in the malaria vector *Anopheles stephensi*. *Nucleic Acids Res.* 31, e85
- 43 Wang, S. *et al.* (2011) Local adaptation of an introduced transgenic insect fungal pathogen due to new beneficial mutations. *Proc. Natl. Acad. Sci. U.S.A.* 108, 20449–20454
- 44 Farenhorst, M. *et al.* (2009) Fungal infection counters insecticide resistance in African malaria mosquitoes. *Proc. Natl. Acad. Sci. U.S.A.* 106, 17443–17447
- 45 Mnyone, L.L. *et al.* (2009) First report of *Metarhizium anisopliae* IP 46 pathogenicity in adult *Anopheles gambiae* s.s. and *An. arabiensis* (Diptera; Culicidae). *Parasit. Vectors* 2, 59
- 46 Scholte, E.J. *et al.* (2005) An entomopathogenic fungus for control of adult African malaria mosquitoes. *Science* 308, 1641–1642
- 47 Blanford, S. *et al.* (2005) Fungal pathogen reduces potential for malaria transmission. *Science* 308, 1638–1641
- 48 Hancock, P.A. *et al.* (2009) An age-structured model to evaluate the potential of novel malaria-control interventions: a case study of fungal biopesticide sprays. *Proc. Biol. Sci.* 276, 71–80
- 49 Thomas, M.B. and Read, A.F. (2007) Can fungal biopesticides control malaria? *Nat. Rev. Microbiol.* 5, 377–383
- 50 Fang, W.G. *et al.* (2011) Development of transgenic fungi that kill human malaria parasites in mosquitoes. *Science* 331, 1074–1077
- 51 Ward, T.W. *et al.* (2001) *Aedes aegypti* transducing densovirus pathogenesis and expression in *Aedes aegypti* and *Anopheles gambiae* larvae. *Insect Mol. Biol.* 10, 397–405
- 52 Ren, X. *et al.* (2008) Viral paratransgenesis in the malaria vector *Anopheles gambiae*. *PLoS Pathog.* 4, e1000135

- 53 Ma, M. *et al.* (2011) Discovery of DNA viruses in wild-caught mosquitoes using small RNA high throughput sequencing. *PLoS ONE* 6, e24758
- 54 Carlson, J. *et al.* (2006) Dengroviruses for control and genetic manipulation of mosquitoes. *Adv. Virus Res.* 68, 361–392
- 55 Weiss, B. and Aksoy, S. (2011) Microbiome influences on insect host vector competence. *Trends Parasitol.* 27, 514–522
- 56 Durvasula, R.V. *et al.* (1997) Prevention of insect-borne disease: an approach using transgenic symbiotic bacteria. *Proc. Natl. Acad. Sci. U.S.A.* 94, 3274–3278
- 57 Chang, T.L. *et al.* (2003) Inhibition of HIV infectivity by a natural human isolate of *Lactobacillus jensenii* engineered to express functional two-domain CD4. *Proc. Natl. Acad. Sci. U.S.A.* 100, 11672–11677
- 58 Favia, G. *et al.* (2007) Bacteria of the genus *Asaia* stably associate with *Anopheles stephensi*, an Asian malarial mosquito vector. *Proc. Natl. Acad. Sci. U.S.A.* 104, 9047–9051
- 59 Rao, S. *et al.* (2005) Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. *Proc. Natl. Acad. Sci. U.S.A.* 102, 11993–11998
- 60 Riehle, M.A. *et al.* (2007) Using bacteria to express and display anti-*Plasmodium* molecules in the mosquito midgut. *Int. J. Parasitol.* 37, 595–603
- 61 Straif, S.C. *et al.* (1998) Midgut bacteria in *Anopheles gambiae* and *An. funestus* (Diptera: Culicidae) from Kenya and Mali. *J. Med. Entomol.* 35, 222–226
- 62 Wang, Y. *et al.* (2011) Dynamic gut microbiome across life history of the malaria mosquito *Anopheles gambiae* in Kenya. *PLoS ONE* 6, e24767
- 63 Pumpuni, C.B. *et al.* (1996) Bacterial population dynamics in three anopheline species: the impact on *Plasmodium* sporogonic development. *Am. J. Trop. Med. Hyg.* 54, 214–218
- 64 Andrews, J.H. and Harris, R.F. (2000) The ecology and biogeography of microorganisms on plant surfaces. *Annu. Rev. Phytopathol.* 38, 145–180
- 65 Pusey, P.L. (2002) Biological control agents for fire blight of apple compared under conditions limiting natural dispersal. *Plant Dis.* 86, 639–644
- 66 Pusey, P.L. (1997) Crab apple blossoms as a model for research on biological control of fire blight. *Phytopathology* 87, 1096–1102
- 67 Dong, Y. *et al.* (2009) Implication of the mosquito midgut microbiota in the defense against malaria parasites. *PLoS Pathog.* 5, e1000423
- 68 Meister, S. *et al.* (2005) Immune signaling pathways regulating bacterial and malaria parasite infection of the mosquito *Anopheles gambiae*. *Proc. Natl. Acad. Sci. U.S.A.* 102, 11420–11425
- 69 Cirimotich, C.M. *et al.* (2011) Natural microbe-mediated refractoriness to *Plasmodium* infection in *Anopheles gambiae*. *Science* 332, 855–858
- 70 Boissiere, A. *et al.* (2012) Midgut microbiota of the malaria mosquito vector *Anopheles gambiae* and interactions with *Plasmodium falciparum* infection. *PLoS Pathog.* 8, e1002742
- 71 Damiani, C. *et al.* (2008) Paternal transmission of symbiotic bacteria in malaria vectors. *Curr. Biol.* 18, R1087–R1088
- 72 Favia, G. *et al.* (2008) Bacteria of the genus *Asaia*: a potential paratransgenic weapon against malaria. *Adv. Exp. Med. Biol.* 627, 49–59
- 73 Werren, J.H. *et al.* (2008) *Wolbachia*: master manipulators of invertebrate biology. *Nat. Rev. Microbiol.* 6, 741–751
- 74 Iturbe-Ormaetxe, I. *et al.* (2011) *Wolbachia* and the biological control of mosquito-borne disease. *EMBO Rep.* 12, 508–518
- 75 Moreira, L.A. *et al.* (2009) A *Wolbachia* symbiont in *Aedes aegypti* limits infection with dengue, *Chikungunya*, and *Plasmodium*. *Cell* 139, 1268–1278
- 76 Kambris, Z. *et al.* (2009) Immune activation by life-shortening *Wolbachia* and reduced filarial competence in mosquitoes. *Science* 326, 134–136
- 77 Bian, G. *et al.* (2010) The endosymbiotic bacterium *Wolbachia* induces resistance to dengue virus in *Aedes aegypti*. *PLoS Pathog.* 6, e1000833
- 78 Hughes, G.L. *et al.* (2011) *Wolbachia* infections are virulent and inhibit the human malaria parasite *Plasmodium falciparum* in *Anopheles gambiae*. *PLoS Pathog.* 7, e1002043
- 79 Walker, T. and Moreira, L.A. (2011) Can *Wolbachia* be used to control malaria? *Mem. Inst. Oswaldo Cruz* 106, 212–217
- 80 Ignatova, E.A. *et al.* (1996) The yeast flora of blood-sucking mosquitoes. *Mikrobiol. Z.* 58, 12–15
- 81 Ricci, I. *et al.* (2011) The yeast *Wickerhamomyces anomalus* (*Pichia anomala*) inhabits the midgut and reproductive system of the Asian malaria vector *Anopheles stephensi*. *Environ. Microbiol.* 13, 911–921
- 82 Ricci, I. *et al.* (2011) Different mosquito species host *Wickerhamomyces anomalus* (*Pichia anomala*): perspectives on vector-borne diseases symbiotic control. *Antonie Van Leeuwenhoek* 99, 43–50
- 83 Hurwitz, I. *et al.* (2011) Paratransgenic control of vector borne diseases. *Int. J. Biol. Sci.* 7, 1334–1344
- 84 Riehle, M.A. and Jacobs-Lorena, M. (2005) Using bacteria to express and display anti-parasite molecules in mosquitoes: current and future strategies. *Insect Biochem. Mol. Biol.* 35, 699–707
- 85 Yoshida, S. *et al.* (1999) A single-chain antibody fragment specific for the *Plasmodium berghei* ookinete protein Pbs21 confers transmission blockade in the mosquito midgut. *Mol. Biochem. Parasitol.* 104, 195–204
- 86 Tzschaschel, B.D. *et al.* (1996) An *Escherichia coli* hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIeB subunit by *Salmonella typhimurium* aroA. *Nat. Biotechnol.* 14, 765–769
- 87 Bisi, D.C. and Lampe, D.J. (2011) Secretion of anti-*Plasmodium* effector proteins from a natural *Pantoea agglomerans* isolate by using PelB and HlyA secretion signals. *Appl. Environ. Microbiol.* 77, 4669–4675
- 88 Benedict, M.Q. and Robinson, A.S. (2003) The first releases of transgenic mosquitoes: an argument for the sterile insect technique. *Trends Parasitol.* 19, 349–355
- 89 Nolan, T. *et al.* (2011) Developing transgenic *Anopheles* mosquitoes for the sterile insect technique. *Genetica* 139, 33–39
- 90 Alphey, L. *et al.* (2008) Insect population suppression using engineered insects. *Adv. Exp. Med. Biol.* 627, 93–103
- 91 Carter, V. and Hurd, H. (2010) Choosing anti-*Plasmodium* molecules for genetically modifying mosquitoes: focus on peptides. *Trends Parasitol.* 26, 582–590
- 92 Ghosh, A. *et al.* (2003) Molecular strategies to study *Plasmodium*-mosquito interactions. *Trends Parasitol.* 19, 94–101
- 93 Jaynes, J.M. *et al.* (1988) In vitro cytotoxic effect of novel lytic peptides on *Plasmodium falciparum* and *Trypanosoma cruzi*. *FASEB J.* 2, 2878–2883
- 94 Arrighi, R.B. *et al.* (2008) Cell-penetrating peptide TP10 shows broad-spectrum activity against both *Plasmodium falciparum* and *Trypanosoma brucei brucei*. *Antimicrob. Agents Chemother.* 52, 3414–3417
- 95 Gao, B. *et al.* (2009) AdDLP, a bacterial defensin-like peptide, exhibits anti-*Plasmodium* activity. *Biochem. Biophys. Res. Commun.* 387, 393–398
- 96 Gao, B. *et al.* (2010) Characterization of two linear cationic antimalarial peptides in the scorpion *Mesobuthus eupeus*. *Biochimie* 92, 350–359
- 97 Tian, C. *et al.* (2008) Gene expression, antiparasitic activity, and functional evolution of the drosomycin family. *Mol. Immunol.* 45, 3909–3916
- 98 Li, F. *et al.* (2005) An anti-chitinase malaria transmission-blocking single-chain antibody as an effector molecule for creating a *Plasmodium falciparum*-refractory mosquito. *J. Infect. Dis.* 192, 878–887
- 99 Franz, A.W. *et al.* (2009) Stability and loss of a virus resistance phenotype over time in transgenic mosquitoes harbouring an antiviral effector gene. *Insect Mol. Biol.* 18, 661–672
- 100 Muller, G.C. *et al.* (2010) Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the *Anopheles gambiae* complex in Mali, West Africa. *Malar. J.* 9, 210